Using short selfie videos to measure walking and speech changes in people with MS
Official title: "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Run by University of California, San Francisco · NCT07222618 · Data updated 2026-11-12
This project will test whether short selfie videos taken by people with MS can reliably show walking and speech changes similar to what clinicians see in person.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | October 1, 2028 |
| Study ends | October 1, 2028 |
| Registry record updated | October 31, 2025 |
| Trial ID | NCT07222618 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a physician diagnosis of MS who are 18 or older, have EDSS under 6.5, can consent (or have a surrogate/LAR), and own a device capable of video recording are ideal candidates.
✕Probably not a fit
People with EDSS 6.5 or higher, those without any video-capable device or without a surrogate to provide consent, and patients whose important symptoms are not captured by walking or speech may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants will record five brief "selfie" videos at baseline and again at 3, 6, and 12 months and upload them through a secure web portal, while attending in-person visits at baseline, 6 months, and 12 months for standard clinical measures. The approach uses participants' own devices (smartphones, tablets, laptops) and focuses on low-burden, real-world capture of walking and speech. Investigators will compare remote video-derived measures to in-person exam findings to test feasibility, validity, and barriers to adoption. The team plans to share accessible protocols and metrics if the remote method proves reliable.
Why it matters
Potential benefit: If successful, this could enable low-cost, low-burden remote monitoring of walking and speech in MS so clinicians and researchers can track changes more frequently and accessibly.
How similar studies have gone: Preliminary data from the investigators and related digital-biomarker work support feasibility and validity, but using patient-acquired selfie videos as a primary remote measure is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient with MS who is above the age of 18 yrs. Participants who are unable to consent for themselves must have a surrogate decision maker or LAR. * Age \> 18 yrs, EDSS - \<6.5, own a video recording device (smartphone, tablet, camera etc). Exclusion Criteria: * Patient unwilling to participate in the study. Participants unable to consent for themselves who do not have a surrogate decision maker or LAR.
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Riley Bove, MD — University of California, San Francisco
- Study coordinator: Kyra Henderson, Study Coordinator
- Email: kyra.henderson@ucsf.edu
- Phone: 415-353-8053
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based functional balance program for people with multiple sclerosis
This project will test whether a home-based functional balance program helps adults with multiple sclerosis improve physical and cognitive function and daily activities.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Safety and dosing of S103 cells in progressive or refractory multiple sclerosis
This trial tests S103 BCMA-CAR T cells in adults with progressive or refractory MS to see if it can be safely given and hint at benefit.
-
TRX319 treatment for people with primary or secondary progressive multiple sclerosis
This trial will test whether the experimental therapy TRX319, given with or without a short bendamustine pre-conditioning, is safe and can slow or improve disability in adults with primary or secondary progressive MS.
-
Ublituximab (Briumvi) for early relapsing MS
This study will test whether giving Ublituximab (Briumvi) about twice a year is safe and changes a blood marker (neurofilament light) in adults with early relapsing MS.
-
At-home full-body stimulation suit to manage spasticity and ataxia in MS
This project will try whether wearing a full-body electrical stimulation suit for six weeks helps people with MS who have spasticity or ataxia reduce symptoms and improve daily functioning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.